Yazar "Boruban, Melih Cem" seçeneğine göre listele
Listeleniyor 1 - 9 / 9
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Biatrial Cardiac Metastases in a Patient with Uterine Cervix Malignant Melanoma(Hindawi Ltd, 2015) Geredeli, Caglayan; Boruban, Melih Cem; Poyraz, Necdet; Artac, Mehmet; Aribas, Alpay; Koral, LokmanPrimary malignant melanomas of uterine cervix are quite rarely seen neoplasms, and long-life prognosis of patients with this disease is poor. Immunohistochemical methods and exclusion of other primary melanoma sites are used to confirm the diagnosis. As with other melanomas, cervix malignant melanomas may also cause cardiac metastases. Cardiac metastases are among rarely seen but more commonly encountered cases, compared to primary cardiac tumors. Here, we present a case of biatrial cardiac metastases in a 73-year-old patient with uterine cervix malignant melanomas. The patient underwent echocardiography, cardiac magnetic resonance imaging, and computed tomography. Our report shows the importance of advanced diagnostic techniques, such as cardiac magnetic resonance, not only for the detection of cardiac masses, but for a better anatomic definition and tissue characterization. Although the cases of malignant melanomas leading to multiple cardiac metastasis were reported in literature, the metastatic concurrence of malignant melanomas in both right and left atriums is quite rarely encountered as metastatic malignant melanomas. Also, another intriguing point in our case is that the primary lesion of our case was stemmed from uterine cervix, but not skin.Öğe Cancer types attributable to cigarette smoking and sociodemographic characteristics(Kare Publ, 2014) Kutlu, Ruhusen; Demirbas, Nur; Boruban, Melih Cem; Guler, TuncOBJECTIVES This study was performed to evaluate the sociodemographic characteristics, smoking status and the frequency of the cancer types attributable to cigarette smoking in the cancer patients treating at Medical Oncology Department. METHODS This descriptive and cross-sectional study was performed among 459 cancer inpatients treating at Medical Oncology Department. Data were obtained via a questionnaire form revealed socio-demographic characteristics, smoking-related attitude and behaviors. RESULTS Of the participants, the mean age was 57.42 +/- 13.29 (range: 1891), 52.9% were male. The prevalence of current smokers was 9.6%, former smokers 48.1%, never-smokers 42.3%. respectively. While respiratory tract cancers (32.1%), GIS (24.3%) and colorectal cancers (18.9%) were seen frequently in the male gender, breast cancer (46.8%) GIS cancers (15.3%) and colorectal cancers (12.5%) were seen frequently in the female. While the frequency of the respiratory tract cancers was 30.6% in the smoker cancer patients, this rate was 4.6% in never smokers. The frequency of the respiratory tract cancers was higher in the smoker cancer patients than never smoker cancer patients (RR=6.65). Of the respiratory tract cancers, 26.0% was attributed to cigarette smoking. CONCLUSION Particularly, smoking plays an important role in the development of lung cancer. Common cancers shows differences according to gender and age. So, the socio-demographic characteristics should be considered while the cancer screening programs are developing.Öğe Clinicopathologic analysis and prognostic factors for survival in early stage patients with ampullary carcinoma.(Amer Soc Clinical Oncology, 2016) Ozdemir, Nuriye; Demirci, Nebi Serkan; Yuksel, Sinemis; Erdem, Gokmen Umut; Odabas, Hatice; Boruban, Melih Cem; Hacibekiroglu, Ilhan[Abstract Not Availabe]Öğe Clinicopathologic analysis and prognostic factors for survival in early stage patients with ampullary carcinoma.(Amer Soc Clinical Oncology, 2016) Ozdemir, Nuriye; Demirci, Nebi Serkan; Yuksel, Sinemis; Erdem, Gokmen Umut; Odabas, Hatice; Boruban, Melih Cem; Hacibekiroglu, Ilhan[Abstract Not Availabe]Öğe Does obesity change the effect of aromatase inhibitors (AIs) on estradiol, leptin, insulin, and IGF-1 serum levels in breast cancer patients?(Amer Soc Clinical Oncology, 2012) Artac, Mehmet; Askin, Dudu; Kiyici, Aysel; Eren, Onder Orhan; Oncel, Mufide; Boruban, Melih Cem; Bozcuk, Hakan Sat[Abstract Not Availabe]Öğe Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab(Springer, 2017) Artac, Mehmet; Uysal, Mukremin; Karaagac, Mustafa; Korkmaz, Levent; Er, Zehra; Guler, Tunc; Boruban, Melih CemPurpose Metastatic colorectal cancer (mCRC) is a lethal disease and fluorouracil-leucovorin-irinotecan (FOLFIRI) plus bevacizumab (bev) is a standard approach. Hence, there is a strong need for identifying new prognostic factors to show the efficacy of FOLFIRI-bev. Methods This is a retrospective study including patients (n = 90) with mCRC from two centers in Turkey. Neutrophil/lymphocyte (N/L) ratio, platelet count, albumin, and Creactive protein (CRP) were recorded before FOLFIRI-bev therapy. The efficacy of these factors on progression-free survival (PFS) was analyzed with Kaplan Meier and Cox regression analysis. And the cutoff value of N/L ratio was analyzed with ROC analysis. Results The median age was 56 years (range 21-80). Forty-seven percent of patients with N/L ratio >2.5 showed progressive disease versus 43 % in patients with N/L ratio <2.5 (p = 0.025). The median PFS was 8.1 months for the patients with N/L ratio >2.5 versus 13.5 months for the patients with N/L ratio <2.5 (p = 0.025). At univariate Cox regression analysis, high baseline neutrophil count, LDH, N/L ratio, and CRP were all significantly associated with poor prognosis. At multivariate Cox regression analysis, CRP was confirmed to be a better independent prognostic factor. CRP variable was divided into above the upper limit of normal (ULN) and normal value. The median PFSs of the patients with normal and above ULN were 11.3 versus 5.8 months, respectively (p = 0.022). Conclusions CRP and N/L ratio are potential predictors for advanced mCRC treated with FOLFIRI-bev.Öğe The prognostic role of XRCC1, ERCC1, ERCC2, and TP53 single nucleotide polymorphisms (SNPs) in resected non-small cell lung cancer (NSCLC)(Lippincott Williams & Wilkins, 2013) Geredeli, Caglayan; Artac, Mehmet; Yildirim, Selman; Dede, Isa; Inal, Ali; Guler, Tunc; Boruban, Melih Cem[Abstract Not Availabe]Öğe Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer(Sage Publications Ltd, 2015) Geredeli, Caglayan; Artac, Mehmet; Yildirim, Selman; Inal, Ali; Dede, Isa; Guler, Tunc; Boruban, Melih CemIdentification of biomarkers used for the prognostic evaluation of non-small cell lung cancer (NSCLC) patients is important. The aim of this study was to evaluate the potential prognostic value of XRCC1, ERCC1, ERCC2, and TP53 single nucleotide polymorphisms (SNPs) in completely resected NSCLC patients. In total, 130 patients, surgically treated for NSCLC between 2000 and 2012, were included. An analysis of SNPs from peripheral blood cells was performed by polymerase chain reaction. XRCC1 Arg399Gln, ERCC1 Asn118Asn, ERCC2 Lys751Gln, and TP53 Arg72Pro polymorphisms were evaluated in conjunction with clinical and pathological parameters and survival. Kaplan-Meier method and Cox regression analysis were used. Median age rate was 59.3, ranging between 36 and 78 years. Median relapse-free survival duration (RFS) was found as 46.2 months. In those with ERCC2 CC allele, median RFS was detected as 28.3 months (95 % confidence interval (CI), 20.8-35.8), 46.9 months in those with CT heterozygous (95 % CI, 18.6-75.2), and 80.1 months for those with TT mutant allel (95 % CI, 33.0-127.2). Median RFS was seen to be longer in mutant group and also statistically significant (P = 0.018). Additionally, upon evaluating CC normal group with CT + TT alleles including mutant alleles, median RFS was found as 56.5 months (95 % CI, 24.6-88.4) in CT + TT group, and this was statistically significant (P = 0.005) Also, median RFS was 15.1 months in those including ERCC2 CC allele and 56.5 months in CT + TT allele in the group with no adjuvant treatment (P = 0.001). In conclusion, our study showed that ERCC2/XPD polymorphism is an independent prognostic factor in operated NSCLC patients, and these findings should be supported with prospective studies.Öğe Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs)(Springer Japan Kk, 2013) Artac, Mehmet; Bozcuk, Hakan; Kiyici, Aysel; Eren, Orhan Onder; Boruban, Melih Cem; Ozdogan, MustafaOur objective was to determine whether serum leptin levels and obesity-related factors could affect outcome for metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs). Sixty MBC patients treated with first line hormonal therapy were enrolled in this study. Median age was 51 years (range 28-75). Median leptin level was 19400 pg/ml (1970-91900) and estradiol level 29.6 pg/ml (4.0-181.9). Factors associated with overall survival in univariate analysis were age and waist-to-hip ratio (WHR), whereas only WHR retained significance in the multivariate analysis. However, no factor was associated with progression-free survival. However, WHR was found to be a significant prognostic marker only if the leptin level was a parts per thousand yen19400 pg/ml (HR = 0.38; 95% CI: 0.16-0.91). This study suggests that serum leptin levels and WHR together may serve as potential prognostic markers in MBC patients treated with AIs.
